Crescent Sterling Ltd. Sells 15 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Crescent Sterling Ltd. trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 402 shares of the biopharmaceutical company’s stock after selling 15 shares during the quarter. Crescent Sterling Ltd.’s holdings in Regeneron Pharmaceuticals were worth $286,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in REGN. Czech National Bank boosted its position in shares of Regeneron Pharmaceuticals by 5.6% in the fourth quarter. Czech National Bank now owns 22,826 shares of the biopharmaceutical company’s stock valued at $16,260,000 after acquiring an additional 1,209 shares during the period. Jacobs & Co. CA lifted its stake in Regeneron Pharmaceuticals by 0.7% in the 4th quarter. Jacobs & Co. CA now owns 9,191 shares of the biopharmaceutical company’s stock worth $6,547,000 after purchasing an additional 64 shares in the last quarter. First Hawaiian Bank boosted its holdings in Regeneron Pharmaceuticals by 18.8% in the 4th quarter. First Hawaiian Bank now owns 2,995 shares of the biopharmaceutical company’s stock valued at $2,133,000 after purchasing an additional 474 shares during the period. Range Financial Group LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $220,000. Finally, Diversified Trust Co increased its holdings in shares of Regeneron Pharmaceuticals by 93.0% in the fourth quarter. Diversified Trust Co now owns 2,330 shares of the biopharmaceutical company’s stock worth $1,660,000 after purchasing an additional 1,123 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the company. Leerink Partners reaffirmed a “market perform” rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. Piper Sandler cut their price target on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Bank of America restated an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Citigroup assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, November 14th. They issued a “neutral” rating and a $895.00 target price for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,037.33.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $696.88 on Monday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a market cap of $76.58 billion, a P/E ratio of 17.25, a P/E/G ratio of 2.19 and a beta of 0.10. The business’s 50 day moving average price is $751.44 and its 200-day moving average price is $961.06. Regeneron Pharmaceuticals, Inc. has a 52 week low of $691.00 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.